Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/10/2018
SIETES contiene 92571 citas

 
 
 1 a 20 de 170 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Begley S, Empinado H. STAT Plus: CAR-T is a personalized attack on cancer. Here’s how it works. STAT Daily Recap 2018:6. [Ref.ID 102483]
2.Enlace a cita original Cita con resumen
Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon Ch, Harden M, Lennon N, Gabriel S, Rodig S, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017;547:217-21. [Ref.ID 101662]
4. Cita con resumen
Anónimo. FDA allows trials Of Cuban lung cancer vaccine in US. DIA Daily 2016:4. [Ref.ID 100866]
5. Cita con resumen
Hirschler B. AstraZeneca pauses two cancer drug trials' enrolment due to bleeding. Reuters Health News 2016:1. [Ref.ID 100864]
9. Cita con resumen
Pollack A. Immunotherapy drug Opdivo fails clinical trial to expand use. N Y Times (Print) 2016:1. [Ref.ID 100567]
10. Cita con resumen
Villegas S. Enfermedad de Alzheimer: nuevas estrategias terapéuticas. Med Clin (Barc) 2015;145:76-83. [Ref.ID 99323]
11. Cita con resumen
Anagnostou K, Islam S, King Y, Foley L, Pasea L, Bond S, Palmer Ch, Deighton J, Ewan P, Clark A. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet 2014;383:1297-304. [Ref.ID 97408]
12.
Greenhawt MJ. STOPping peanut allergy: the saga of food oral immunotherapy. Lancet 2014;383:1272-4. [Ref.ID 97407]
13. Cita con resumen
Anónimo. Bacilles de Calmette et Guérin et cancers de la vessie. Prescrire 2013;33:734. [Ref.ID 96233]
14.Tiene citas relacionadas
Nelson HS. Is sublingual immunotherapy ready for use in the United States?. JAMA 2013;309:1297-8. [Ref.ID 95145]
15.Enlace a cita originalTiene citas relacionadas Cita con resumen
Lin SY, Erekosima N, Kim JM, Ramanathan M, Suarez-Cuervo C, Chelladurai Y, Ward D, Segal JB. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA 2013;309:1278-88. [Ref.ID 95141]
16. Cita con resumen
Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz PG, Jurcic J, Rosenblat T, Masiak P, Frattini M, Sadelain M. CD19-targeted cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5:177. [Ref.ID 95067]
17. Cita con resumen
Burks AW, Jones SM, Wood RA, Fleischer DM, Sicherer SH, Lindblad RW, Stablein D, Henning AK, Vickery BP, Liu AH, Scurlock AM, Shreffler WG, Plaut M, Sampson HA, for the Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. N Engl J Med 2012;367:233-43. [Ref.ID 93470]
18. Cita con resumen
Ludvigsson J, Krisky D, Casas R, Battelino T, Castaño L, Greening J, Kordonouri O, Otonkoski T, Pozzilli P, Robert J-J, Veeze HJ, Palmer J. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012;366:433-42. [Ref.ID 92306]
19. Cita con resumen
O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffnet P, Wang L, Miller A, Freedman MS, for the TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293-303. [Ref.ID 91534]
20.Tiene citas relacionadas Cita con resumen
Bach J-F. Anti-CD3 antibodies for type 1 diabetes: beyond expectations. Lancet 2011;378:459-60. [Ref.ID 91423]
Seleccionar todas
 
 1 a 20 de 170 siguiente >>